Atrium Therapeutics, Inc. cotiza a 7.75 USD y tiene una capitalización bursátil de $133M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of P…
| Periodo | 2026-11 | 2026-05 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.97 | — | $-1.59 |
| Estimado | $-0.67 | $-1.05 | $-1.30 | $-1.26 |
| Sorpresa | — | +7.6% | — | -26.2% |
| Métrica | RNA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | — | -32.0% | — |
| Current Ratio | 0.07 | 2.84 | -2.77 |
| Debt / Equity | — | 0.28 | — |